Maganin Neocuproine wani abu ne da ake amfani da shi wajen tantance jan ƙarfe, mai launin fari ko rawaya-kasa, wanda ke haifar da haushi. Ana amfani da shi galibi a matsayin maganin rage zafi don tantance jan ƙarfe, tantancewar jan ƙarfe, tantancewar sukari na jini mai yawa; haɗakar halitta. An yi amfani da Neocuproine hydrochloride monohydrate wajen auna narkar da jan ƙarfe a cikin ƙarfen Cu-Ni ta amfani da hanyar launi. An kuma yi amfani da shi wajen shirya maganin rage zafi wajen nazarin gwaje-gwajen ƙarfin antioxidant a cikin samfuran halittu bisa ga hadaddun ƙwayoyin Cu. Ana iya amfani da shi azaman abin da zai fara shirya neocuproine, wanda ake amfani da shi azaman maganin tantancewa don tantance jan ƙarfe a cikin samfuran muhalli ta amfani da dabarar spectrophotometric.
Duk da haka, irin wannan maganin yana da amfani daban-daban a fannin magani. Kwanan nan, Hukumar Kayayyakin Lafiya ta Ƙasa (NMPA) ta ƙasarmu ta amince da tallata Eribulin don maganin marasa lafiya da ke fama da cutar kansar nono ko kuma waɗanda suka kamu da cutar kansar nono a gida waɗanda suka karɓi aƙalla magungunan chemotherapy guda biyu (gami da anthracyclines da taxans) a baya. Ya kawo sabon tsarin magani a fannin maganin chemotherapy na ciwon nono a China, kuma yana kawo ƙarin zaɓuɓɓukan magani ga marasa lafiya.
Eribulin wani maganin hana tubulin ne wanda ba na taxane ba. Ba kamar maganin hana taxane da vinblastine tubulin ba, Eribulin yana da wani tsari na musamman na aiki, wanda ke sa Eribulin Har yanzu yana da tasiri ga marasa lafiya bayan shan magani; Eribulin kuma yana da tasirin da ba ya haifar da guba, gami da sake fasalin jijiyoyin jini, ƙara yawan sauran magunguna a cikin yanayin ciwon daji, haɗa wasu magunguna, da kuma juya ƙwayoyin ciwon daji Canjin epidermal-mesenchymal da sauransu.
Daga cikakken hada sinadarin halichondrin B, amfani da sabbin sinadaran jan ƙarfe a matsayin tsaka-tsaki, zuwa gyaran tsarin Eribulin, zuwa samar da Eribulin a masana'antu, masana kimiyya daga kamfanonin ilimi da magunguna sun shafe sama da shekaru 20 suna bincike. Kayayyakin halitta da aka samo daga teku sun zama magunguna da za su iya magance cutar kansa. Bincike da haɓaka Eribulin ya faru ne saboda sabon sinadarin jan ƙarfe yana da mahimmanci a matsayin babban matsakaiciyar API ɗinsa. Sabon sinadarin jan ƙarfe yana da babban aiki a matsayin maganin magunguna da kuma maganin tsaftace kayan aiki masu inganci.
Tsarin kwayoyin halitta na Eribulin ya ƙunshi cibiyoyin chiral guda 19, kuma matakan haɗakarwa sun kai matakai 62. Har zuwa yanzu, masana'antar har yanzu tana ɗaukar Eribulin a matsayin magani mafi rikitarwa wanda ba shi da peptide wanda aka samar ta hanyar haɗakar sinadarai tsantsa, kuma ana iya kiransa Dutsen Everest a masana'antar haɗakar sinadarai.
Nasarar da aka samu wajen yin amfani da Eribulin wajen samar da magunguna ya nuna sabbin nasarorin da kamfanonin magunguna za su iya samu a fannin hada sinadarai da samar da kayayyaki a masana'antu. Haka kuma, yana kawo karin ra'ayoyi da hanyoyin gano cututtuka da magani ga likitocin kasar Sin. Ana fatan cewa a nan gaba, sabuwar maganin chemotherapeutic Eribulin zai iya kawo sabon fata ga masu fama da cutar kansar nono.
Lokacin Saƙo: Janairu-01-2021